Preventing Cervical Cancer With IUDs
Doctors have long been encouraging women to consider an IUD for contraception, to reduce heavy periods and provide a low dose hormonal option for menopausal hormonal therapy (MHT).
Research continues to show that this is a safe and effective option for women – even teenagers and women who have not had a baby. 
And, there is now a research to show that both the Copper IUD and Mirena IUD can be reliably used for contraception for longer than previously thought. The Copper IUD for 12 years, instead of 10 years. And the Mirena IUD for up to 7 years, instead of 5 years. 
It is advisable, however, to discuss this with your doctor, as the companies that produce these devices have not yet changed their ‘product information’ advice to women.
At this stage, doctors are using this research to reassure women that they don’t need to panic about changing over their IUDs before the 10 and 5 mark…We have a bit of leeway. Phew!
Even more exciting news from the research world is the observation that women who used IUDs have a lower risk of suffering from cervical cancer.
Research – IUDs Can Help Prevent Cervical Cancer
Researchers at the University of Southern California have gathered information from 16 studies involving 12,000 women from across the world and found that women who have used IUDs had a 1/3 lower rate of cervical cancer compared to women who had never used an IUD.
Scientists have two explanations for this amazing discovery of how IUDs can help prevent cervical cancer. One theory is that the precancerous lesions may be destroyed when the IUD is inserted and removed.
The second theory is that the IUD stimulates the immune system to destroy the Human Papilloma Virus – the virus that damages cells eventually causing cancer. Wow!
Women with IUDs still need to have Cervical Screening tests every 5 years. Because you’re worth it!
So, make an appointment to talk to Dr Mezzini about an IUD. It might be just the right method of contraception, cycle control or MHT option for you.
Dr Mezzini is an experienced IUD inserter. She is able to use a number of techniques to minimise the discomfort of the insertion procedure, even in women who have never had a pregnancy or a delivery.
Dr Tonia Mezzini is known for offering the best possible advice and treatment options for a person’s sexual health care needs. In particular, she cares for patients with:
- Premenstrual Syndrome and Premenstrual Dysphoric Disorder
- Vulval pain syndromes and vulval skin conditions
- Low libido and pain with intercourse
- Polycystic Ovarian Syndrome
- Gender-affirming hormone therapy
- Complex contraceptive choices
- Sexually transmitted infections such as recurrent genital herpes
- Recurrent bacterial vaginosis
- Recurrent thrush
- Menopause and hormonal concerns
- Chronic pelvic pain in men and women
- Painful periods and endometriosis
- Information about sexual health
- Women's Health after cancer treatment
- Androgen deficiency in men
Would you like to know more about how IUDs can help prevent cervical cancer? – Contact Dr Tonia Mezzini today.
 Committee on Practice Bulletins – Gynaecology, Long-Acting Reversible Contraception Work Group. Practice Bulletin 186: Long-acting reversible contraception: Implants and Intrauterine devices. Obstet Gynaecol 2017;130:e251-e269.
 Wu JP, Pickle S. Extended use of the intrauterine device: A literature review and recommendations for clinical practice. Contraception 2014;89:495-503.
 McNicholas C, Swor E, Wan L et al. Prolonged use of the etonogestrel implant and levonogestrel intrauterine device: 2 years beyond the Food and Drug approved duration. American J Obs and Gynae 2017 Jun:216(6):586.e6. doi10.1016
 Cortessis VK, Barrett M, Brown Wade N et al. Intrauterine device use and cervical cancer risk: A systematic review and meta-analysis. Ostet Gynaecol 2017;doi:10.1097/AOG.0000000000002307.
 Castellsague X, Diaz M, Vaccarella S et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: A pooled analysis of 26 epidemiological studies. Lancet Oncol 2011;12:1023-1031.